If you have been reading about lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The physics of lyophilization depends on phase boundaries and heat and mass transfer. During primary drying, heat supplied to the product must equal the latent heat of sublimation, while water vapor moves through the drying cake to the condenser. If shelf temperature or pressure is set too high, the ice front can exceed the collapse temperature, causing meltback or pore collapse. If conditions are too cold, drying slows and costs rise. Formulation excipients, vial geometry, and freezing rate alter these limits.
Equipment for lyophilization includes a vacuum chamber, temperature-controlled shelves, a condenser, and a vacuum pump. A refrigeration system cools the shelves and condenser below the product's freezing point. Process monitoring often uses Pirani and capacitance manometers, thermocouples, and resistance sensors. Cycle development balances product quality with time and energy use. Some products are annealed during freezing to improve crystallization of bulking agents. Open questions remain about scaling cycles between laboratory, pilot, and production freeze-dryers.
Lyophilization, also called freeze-drying, removes water from a frozen material by sublimation under reduced pressure. The process begins with freezing, which converts free water into ice and may also produce a glassy phase. Primary drying then lowers chamber pressure so ice sublimes directly to vapor without passing through a liquid stage. Secondary drying raises the temperature modestly to remove bound water. The result is a porous, dry solid that usually reconstitutes quickly. Each stage influences pore structure, residual moisture, and stability.
Regulatory expectations for lyophilized products focus on consistent manufacture and documented stability. Batches are often monitored for moisture, appearance, potency, and sterility where applicable. Process parameters such as shelf temperature, chamber pressure, and drying time are recorded and controlled within validated ranges. Open questions remain about how best to predict long-term stability from short accelerated studies, especially for complex biologics. Variations in freezing rate and ice crystal size can produce differences that are not always visible but may affect performance.
After drying, a lyophilized product is usually sealed under vacuum or an inert gas to limit moisture uptake. Residual water content is measured because small changes can alter chemical stability and cake appearance. Storage temperature depends on the material; many biological products are kept at 2–8 °C, while some require −20 °C or colder. Exposure to ambient humidity during handling can cause the porous solid to absorb water and collapse. Container closures and stoppers are therefore selected for low moisture transmission and compatibility.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Freeze-drying; lyophilisation; cryodesiccation | Regional spelling and historical terms. |
| Primary drying pressure | 0.05-0.5 mbar (5-50 Pa) | Kept below the triple point of water; product-specific. |
| Shelf temperature range | -40 to +40 °C | Freezing, primary, and secondary stages use different set points. |
| Cycle duration | 12-72 hours | Depends on fill volume, formulation, and equipment. |
| Condenser temperature | -50 to -80 °C | Must remain below the product's ice temperature. |
After primary drying, secondary drying removes water that remains bound to the material. This stage raises the shelf temperature while maintaining low pressure, which encourages desorption of unfrozen water. Residual moisture can be reduced to a low percentage, improving stability for many products. The process parameters, including freezing rate, shelf temperature, and chamber pressure, influence the final pore structure and reconstitution behavior. Control of these variables helps prevent collapse or meltback during drying.
A formulation often contains excipients that protect the active ingredient during freezing and drying. Bulking agents provide structure, while lyoprotectants stabilize sensitive molecules. The freezing step can produce ice crystals whose size and distribution affect the drying rate, and cycle design includes freezing, annealing, and drying phases. If the product temperature rises above a critical value, the cake may collapse or lose its porous structure. Successful lyophilization therefore depends on the interaction between formulation, equipment, and cycle design.
After lyophilization, the product is usually a porous cake or powder with a large internal surface area. This structure can absorb moisture quickly if exposed to humid air, so vials are sealed under vacuum or an inert gas. Moisture uptake may lower the glass transition temperature of the dried matrix and accelerate chemical or physical degradation. Storage conditions therefore depend on the formulation, container, and intended shelf life. Some products remain stable at room temperature, while others require refrigeration or freezing.
Quality control for lyophilized products includes appearance, cake structure, reconstitution time, pH, residual moisture, and potency. Residual moisture is a key attribute because excess water can reduce stability, while excessively low moisture may cause structural changes or aggregation in some systems. Stability studies compare real-time and accelerated conditions to estimate shelf life. Analytical methods must be validated for the specific matrix, container, and moisture range. Sterility and container integrity are also monitored for sterile products.
Formulation composition influences whether freeze-drying produces an intact cake or a collapsed mass. Excipients such as sugars and polymers can raise the collapse temperature and provide bulk during drying. The critical temperature for primary drying is often the collapse temperature or the glass transition temperature of the maximally concentrated phase. If the product temperature exceeds this threshold, the frozen matrix may soften and lose structure. Established practice therefore links shelf temperature and chamber pressure to the formulation's thermal properties.
The physics of freeze-drying couples heat transfer, mass transfer, and phase change. Heat supplied through the shelf must reach the sublimation front without melting the ice or degrading the product. Water vapor then travels through the already dried layer and leaves the chamber, where low pressure and cold traps keep it from returning. The dried layer acts as a resistance to vapor flow, so drying rate changes as the front recedes. Open questions remain about how pore structure and formulation heterogeneity affect drying uniformity at larger scales.
Lyophilization removes water from a frozen material by sublimation under reduced pressure. The process begins with freezing, which converts liquid water into ice and concentrates dissolved solids. Primary drying then lowers chamber pressure so ice changes directly into vapor without passing through a liquid phase. Secondary drying raises the shelf temperature to remove bound water that remains after ice sublimation. The result is a dry, porous structure that can be reconstituted later.
Misconceptions about lyophilization include the idea that dried products are indefinitely stable or that vacuum sealing eliminates all degradation. Chemical reactions can continue in the solid state, and some proteins lose activity even at low moisture. Another misconception is that any freeze-dryer cycle can be scaled by time alone; heat and mass transfer differ with equipment and load. Open questions remain about predicting long-term stability from short accelerated studies, particularly for amorphous formulations. Real-time stability data remain the standard for shelf-life assignment.
After lyophilization, the dried product is often sealed under vacuum or an inert gas to limit moisture and oxygen exposure. Vials, stoppers, and seals must maintain their barrier throughout shelf life. Storage temperature depends on product sensitivity: some cakes tolerate controlled room temperature, while labile biologics require refrigeration. Humidity is a critical variable because dried cakes are hygroscopic and can absorb water when exposed to air. Handling procedures therefore limit open-vial time and use desiccated environments for sampling.
Quality control for lyophilized materials examines appearance, reconstitution time, residual moisture, and mechanical integrity. An acceptable cake is usually uniform and porous, though appearance alone does not prove stability. Karl Fischer titration is a common method for water content, while differential scanning calorimetry can reveal glass transition events. Stability studies track potency, aggregation, and moisture over time under defined temperature and humidity conditions. Specifications are product-specific and may include sterility and endotoxin tests for sterile preparations.
Halliwell B, Watt F, Minqin R. (2023) Iron and atherosclerosis: Lessons learned from rabbits relevant to human disease. Free Radic. Biol. Med. 209, 165–170. Yau YF, Cheah IK, Mahendran R, Tang RMY, Chua RY, Goh RES, Feng L, Li J, Kua EH, Chen C, Halliwell B. (2024) Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study. J. Alzheimer's Disease 102, 841–854.
tRFs are not restricted to humans and have been shown to exist in multiple organisms. Two online tools are available for those wishing to learn more about tRFs: the framework for the interactive exploration of mitochondrial and nuclear tRNA fragments (MINTbase) and the relational database of Transfer RNA related Fragments (tRFdb Archived 2024-03-15 at the Wayback Machine). MINTbase also provides a naming scheme for the naming of tRFs called tRF-license plates (or MINTcodes) that is genome independent; the scheme compresses an RNA sequence into a shorter string.
Such a brilliant song. I'm very proud of Layne for writing it. When I've stepped up vocally in the past he's been so supportive, and here was a fine example of him stepping up with the guitar and writing a masterpiece. In 1994, Alice in Chains released their third EP, Jar of Flies. It debuted at number one, making it the first Alice in Chains release—and the first-ever EP—to do so. The other members of Alice in Chains, seeing Staley's deteriorating condition, opted not to tour in support of Jar of Flies. Following the album's release, Staley entered a rehabilitation clinic and began to work on a side project with several Seattle musicians, Mike McCready of Pearl Jam, Barrett Martin of Screaming Trees and John Baker Saunders of The Walkabouts. The band worked on material for several months and played its first show on October 12, 1994, at the Crocodile Cafe in Seattle under the name "The Gacy Bunch". Within a few weeks, the band changed its name to Mad Season. In January 1995, Mad Season performed two songs on Pearl Jam's Self-Pollution satellite radio broadcast, "Lifeless Dead" and "I Don't Know Anything". The band completed an album, titled Above, which was released in March 1995. The first single, "River of Deceit", became a modest success on alternative radio. A live performance filmed at the Moore Theatre in Seattle was released in August 1995 as a home video, Live at the Moore.
== Sustainable cities == Sustainable Cities Index 2018: Bangkok ranked 80 of 100 cities (1=best; 100=worst). Other ASEAN cities ranked were: Singapore, 4; Kuala Lumpur, 67; Jakarta, 94; Manila, 95; Hanoi. 98. Sustainable Cities Index 2016: In this study by Arcadis NV, a Dutch design, engineering, and management consulting company, Bangkok ranked 67 of 100 (1=best; 100 worst) global cities. Other ASEAN cities ranked were Singapore, 2; Kuala Lumpur, 55; Hanoi, 87; Jakarta, 88; and Manila, 96.
== Scientific work == Her early research focused on connective tissue matrix biology and tumour matrix biology, particularly the role of tumor-associated macrophages. In recognition of her contributions, she received the Distinguished Scientist Award of the Japanese Society for the Promotion of Science (1992), which led to a visiting professorship at Gifu University in the first semester of the academic year 1992/93. At the request of CRC Press (Boca Raton, USA), she edited the handbook Tumor Matrix Biology (1995). Her public health research focuses on the determinants of premature mortality in Hungary and of cancer and cardiovascular diseases. Her current work investigates the impact of genetic and environmental risk factors and social inequalities on population health. Under her leadership, pioneering and widely cited studies have been conducted on the health status and health behavior of the Roma population. She also supervised PhD graduates.
Sources: en.wikipedia.org
=== Direct Chemical Synthesis === Although the focus has primarily been on enzymatic approaches for overcoming length limitations with oligonucleotide synthesis, a proposed alternative is direct chemical synthesis. Standard oligo-synthesis is done on porous materials, such as controlled pore glass (CPG). However, this environment introduces challenges as sequence length increases. Longer strands take up more space within the pores and limit reagent access, which results in lower coupling efficiency and a greater number of truncated sequences in a solution. One innovative approach includes chemically synthesizing the oligonucleotides on a smooth surface, as opposed to porous material, to improve coupling efficiency while additionally utilizing the purification strategy, catching-by-polymerization (CBP), to selectively isolate full-length oligos in a solution. Performing chemical synthesis on a smooth surface, such as glass wool or glass beads, reduces steric strain and congestion, thus providing alternative solid support benefitting long-oligos.
==== New Zealand ==== In February 2010, Medsafe announced Paradex and Capadex (forms of dextropropoxyphene) were being withdrawn from the marketplace due to health issues, and withdrawal in other countries.
Onyx Pharmaceuticals, Inc. was a pharmaceutical company headquartered in South San Francisco, California that developed and marketed cancer treatment medications. It was founded and incorporated with the California Secretary of State in February 1992 by venture capitalist Kevin J. Kinsella and Frank McCormick, Ph.D., FRS, D.Sc. (Hon.), a renowned British-American biochemist. McCormick served as the chief scientific officer until 1996, while Kinsella chaired the company's board of directors. On March 26, 1996, Onyx withdrew its corporate registration with the California Secretary of State and reincorporated in the state of Delaware in advance of successfully taking the company public on the NASDAQ exchange using National Market symbol ONXX on May 9, 1996. In 2009, the company acquired private biotechnology company Proteolix for US$276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" in an industry survey conducted by the ISI Group. Onyx president and CEO N. Anthony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, by the end of August 2013, Amgen announced that it was acquiring Onyx in an agreed US$10.4 billion deal.
Herein, the electron donor NADPH is used as the reducing agent, ultimately converting the β-keto group of β-ketoacyl-ACP into the β-hydroxyl group of β-hydroxyacyl-ACP. The fifth step of fatty acid elongation is the dehydration of β-hydroxyacyl-ACP to enoyl-ACP, in a reaction catalyzed by 3-hydroxyacyl-ACP dehydratase. 3-hydroxyacyl-ACP dehydratase removes one molecule of H2O to form a double bond between the C2–C3 carbons of β-hydroxyacyl-ACP, thereby saturating the chain and producing enoyl-ACP. The sixth step of fatty acid elongation is the reduction of enoyl-ACP to butyryl-ACP, in a reaction catalyzed by enoyl-ACP reductase. Herein, enoyl-ACP reductase reduces the C2–C3 double bond of enoyl-ACP into a saturated acyl-ACP using one molecule NADPH as the electron donor. The production of butyryl-ACP thus marks the completion of the first cycle of fatty acid elongation, and the reaction sequence thereafter repeats again (condensation → reduction → dehydration → reduction). At the beginning of the second cycle, butyryl-ACP condenses with a molecule of malonyl-ACP, forming the six-carbon β-ketoacyl-ACP molecule and one molecule of CO2. The next three reactions within the second cycle (reduction → dehydration → reduction) convert the six-carbon β-ketoacyl-ACP into a six-carbon ACP molecule, which thus marks the completion of the second cycle of fatty acid elongation, and a third cycle can thereafter begin. These elongation cycles continue (x7) until a (16C) acyl-ACP molecule is formed.
Sources: en.wikipedia.org
Simple drying usually removes water by evaporation from a liquid or solid, often with heat. Lyophilization first freezes the material and then removes ice by sublimation under vacuum. This avoids prolonged exposure to liquid water and high temperatures.
Reduced pressure lowers the boiling point of water and allows ice to sublime at temperatures below freezing. It also helps remove water vapor from the product toward the condenser. The exact pressure is chosen to stay below the triple point of water.
No. Materials with low solids content or high volatile solvents may form weak or collapsed cakes. Some proteins and cells require stabilizers to survive freezing and drying stresses. Feasibility depends on formulation and process design.
Most are held in sealed containers at controlled temperatures, often 2–8 °C, while some require frozen storage. Protection from moisture and light helps preserve the dry matrix. Exact conditions are set by the manufacturer or study protocol.